Lyell Immunopharma (LYEL)
(Delayed Data from NSDQ)
$1.15 USD
+0.02 (1.77%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $1.19 +0.04 (3.48%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Lyell Immunopharma, Inc. [LYEL]
Reports for Purchase
Showing records 1 - 10 ( 10 total )
Company: Lyell Immunopharma, Inc.
Industry: Medical - Drugs
Initial LYL797 Data Raise Questions; Downgrading to Neutral With $1 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Lyell Immunopharma, Inc.
Industry: Medical - Drugs
First Clinical Data Imminent; 1Q24 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Lyell Immunopharma, Inc.
Industry: Medical - Drugs
A Catalyst-Rich Year-LYL797 Data in 1H24 Next; Lowering PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Lyell Immunopharma, Inc.
Industry: Medical - Drugs
First TIL Approval Validates Cell Therapy Class
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Lyell Immunopharma, Inc.
Industry: Medical - Drugs
All Eyes on Clinical Data in 2024; 3Q23 Financials; Lowering PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Lyell Immunopharma, Inc.
Industry: Medical - Drugs
Pipeline Advancing; Two Key 2024 Catalysts; 2Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Lyell Immunopharma, Inc.
Industry: Medical - Drugs
Timelines on Track; 1Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Lyell Immunopharma, Inc.
Industry: Medical - Drugs
2022 Financial Results Reported; Modulating PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Lyell Immunopharma, Inc.
Industry: Medical - Drugs
SITC Presentations This Week; 3Q22 Financial Results; Modulating PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Lyell Immunopharma, Inc.
Industry: Medical - Drugs
Supercharging Cell Therapies to Become Effective and Resilient in Solid Tumors; Initiating at Buy and $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
|